Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, is investigating whether NovoCure Limited (“NovoCure” or the “Company”) (NYSE: NVCR) and certain of its officers and directors issued false and/or misleading statements and/or failed to disclose information pertinent to investors in violation of federal securities laws. If you purchased or otherwise own NovoCure securities, and have suffered a loss, you are encouraged to contact Jonathan Zimmerman at (888) 398-9312 for more information.
NovoCure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its Tumor Treating Fields ("TTFields") therapy.
On June 6, 2023, NovoCure issued a press release announcing "positive results" from the Phase 3 LUNAR clinical trial evaluating the use of its TTFields therapy together with standard therapies for the treatment of non-small cell lung cancer. Despite reporting an observable difference in median overall survival between patients receiving TTFields, combined with standard therapies compared patients treated only with standard therapies, analysts expressed concerns about the test population and the commercial prospects of the device.
On this news, NovoCure's stock fell from $82.51 per share to $47 per share, representing a decline of over 43%.
What You Can Do – CLICK HERE
If you purchased or otherwise own NovoCure securities and have suffered a loss, realized or unrealized, and you wish to discuss this investigation, please contact attorney Jonathan Zimmerman at (888) 398-9312, or at firstname.lastname@example.org.
About Scott+Scott Attorneys at Law LLP
Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.